Phaseline

Targets › HBV

HBV: drug programs, companies and trials

4 programs from 3 companies in 8 trials: 5 Phase 2, 3 Phase 1; Infectious disease, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: the race on HBV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Maryland, BaltimoreImdusiran (AB-729)
HBsAg antisense oligonucleotide
HBVPhase 2Chronic Hepatitis BDec 2026
GSKBepirovirsen
Antisense oligonucleotide targeting hepatitis B virus RNA
HBVPhase 2Hepatitis B; Chronic Hepatitis B Virus InfectionApr 2027
GSKDaplusiran/Tomligisiran
RNAi therapeutic targeting hepatitis B virus and host factors
HBVPhase 2Chronic Hepatitis B Virus InfectionMay 2027
Michael HoelscherTherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)
Heterologous protein prime/MVA boost therapeutic hepatitis B vaccine
HBVPhase 1Chronic Hepatitis BDec 2026

Conditions

Hepatitis B (3) Chronic Hepatitis B (3) Chronic Hepatitis B Virus Infection (2)

Modalities

other (3), protein or peptide (1)

Companies

GSK (2) University of Maryland, Baltimore (1) Michael Hoelscher (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.